WO2004083218A1 - Guanidinderivate und ihre verwendung als neuropeptid ff rezeptor-antagonisten - Google Patents

Guanidinderivate und ihre verwendung als neuropeptid ff rezeptor-antagonisten Download PDF

Info

Publication number
WO2004083218A1
WO2004083218A1 PCT/CH2004/000175 CH2004000175W WO2004083218A1 WO 2004083218 A1 WO2004083218 A1 WO 2004083218A1 CH 2004000175 W CH2004000175 W CH 2004000175W WO 2004083218 A1 WO2004083218 A1 WO 2004083218A1
Authority
WO
WIPO (PCT)
Prior art keywords
tetrahydro
guanidine
benzothiazol
formate
thiazolo
Prior art date
Application number
PCT/CH2004/000175
Other languages
German (de)
English (en)
French (fr)
Inventor
Eva Caroff
Matthias Steger
Oliver Valdenaire
Anja Fecher
Volker Breu
Kurt Hilpert
Heinz Fretz
Thomas Giller
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Priority to MXPA05009855A priority Critical patent/MXPA05009855A/es
Priority to AU2004222224A priority patent/AU2004222224A1/en
Priority to BRPI0408357-1A priority patent/BRPI0408357A/pt
Priority to JP2006504158A priority patent/JP2006520330A/ja
Priority to EP04722212A priority patent/EP1608662A1/de
Priority to CA002518679A priority patent/CA2518679A1/en
Priority to US10/549,685 priority patent/US7727979B2/en
Publication of WO2004083218A1 publication Critical patent/WO2004083218A1/de
Priority to NO20054743A priority patent/NO20054743L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • the present invention relates to guanidine derivatives of the general formula
  • A is a chain of 3-6 optionally substituted C-
  • Atoms means one of which can be replaced by -N (R ') - or -0-;
  • R ' represents hydrogen or a substituent; the ring structure only the two double bonds of
  • Guanidine derivatives of the formula I which contain one or more centers of asymmetry can be used as optically pure enantiomers, as mixtures of enantiomers, for example racemates, or optionally as optically pure diastereomers, as mixtures of diastereomers diastereomeric racemates or as mixtures of diastereomeric racemates.
  • the products defined at the beginning are partly known and partly new, and they have valuable pharmacodynamic properties in that they act as neuropeptide FF receptor antagonists.
  • the present invention relates to the use of the compounds of the formula I defined at the outset and the salts, esters, hydrates and solvates likewise defined at the outset as neuropeptide FF receptor antagonists or for the preparation of corresponding medicaments, in particular for the treatment of pain and hyperalgesia, withdrawal symptoms of alcohol, psychopharmaceutical and nicotine dependency and to improve or eliminate these dependencies, to regulate insulin release, food intake, memory functions, blood pressure, and the electrolyte and energy balance, and to treat urinary incontinence or to manufacture it appropriate drug.
  • the pain to be treated according to the invention can be chronic, acute, long-lasting or transient, and this pain can be of operative, traumatic or pathological origin; an advantage achieved according to the invention is the prevention of opioid tolerance and / or opioid dependence.
  • Neuropeptide FF Neuropeptide FF
  • NPFF neuropeptide FF
  • NPAF neuropeptide AF
  • NPAF neuropeptide AF
  • NPAF H-Ala- Gly-Glu-Gly-Leu-Ser-Ser-Pro Phe-Trp-Ser-Leu-Ala-Ala-Pro-Gln-Arg-Phe-NH 2 [99588-52-0]
  • NPAF neuropeptide AF
  • NPAF neuropeptide AF
  • NPAF neuropeptide AF
  • NPAF neuropeptide AF
  • NPAF neuropeptide AF
  • NPAF H-Ala- Gly-Glu-Gly-Leu-Ser-Ser-Pro Phe-Trp-Ser-Leu-Ala-Ala-Pro-Gln-Arg-Phe-NH 2 [99588-52-0]
  • a related octadecapeptide as Neurotransmitters of the central nervous system discovered in bovine brain
  • NPFF neuropeptide-binding protein
  • Antibodies increase analgesia caused by endogenous and exogenous opioids.
  • NPFF or NPFF analogs By direct injection of NPFF or NPFF analogs into the spinal cord (it), a prophylactic effect with long-lasting opioid-like analgesia and increased pain-relieving effects of morphine was obtained (Gouarderes et al., Eur. J. Pharmacol. 1993, 237 , 73-81; Kontinen and Kalso, Peptides 1995, 16, 973-977).
  • NPFF neuropeptide FF also appears to play a role in physiological processes such as insulin release, regulation of food intake, memory functions, blood pressure regulation and electrolyte balance play (Panula et. al., Prog. Neurobiol. 1996, 48, 461-487).
  • Nervous system such as the hypothalamus, medulla, and dorsal hearing of the spinal cord are restricted.
  • NPFF neuropeptide-like effects peripherally
  • GPCR G-protein coupled receptors
  • NPFF2 is identical to the receptor HLWAR77 originally described as orphan (Elshourbagy et al., J. Biol. Chem. 2000, 275 (34), 25965-71).
  • NPFFl and NPFF2 could be characterized as specific receptors with affinities in the nanomolar and subnanomolar range for the two neuropeptides FF and AF.
  • NPFFl neuropeptide Y
  • NPY Y2 neuropeptide Y
  • cholecystokinin A NPY Yl
  • prolactin-releasing hormones Receptor NPY Y4.
  • NPFFl and NPFF2 were mainly detected in the central nervous system (CNS). In contrast, NPFF2 was found primarily in the spinal cord.
  • NPFF neuropeptides SF
  • NPVF neuropeptide VF
  • NPVF neuropeptide VF
  • NPFF-related peptides both localized on the so-called NPVF gene, bind to the NPFF1 receptor comparatively with higher affinity and selectivity than NPFF and NPAV.
  • the NPVF peptides also block morphine-induced analgesia in acute and inflammatory pain models to a greater extent than NPFF and underline the importance of the NPVF / FF1 system as part of an endogenous anti-opioid mechanism (Q. Liu et al., J. Biol. Chem. 2002, 276 (40), 36961).
  • NPFFl and NPFF2 receptors in addition to their original pain-modulating effects, could also have an influence on the storage and use of body energy (I. Lefrere et al., J. Biol. Chem. 2002, 277 (42), 39169).
  • the DesaminoTyr-Phe-Leu-Phe-Gln-Pro-Gln-Arg-NH 2 peptide has been described as the first NPFF receptor antagonist to counteract the NPFF effects. After icv injection, this peptide attenuated the withdrawal symptoms in the case of morphine dependence (Malin et al., Peptides 1991, 12, 1011-1014). However, this peptide showed no bioavailability in the central nervous system. Optimization of the tripeptide Pro-Gln-Arg-NH 2 in a combinatorial approach led to dansyl-Pro-Gln-Arg-NH 2 , or dansyl-Pro-Ser-Arg-NH 2 , both with improved
  • Arg-Tyr-amide peptoid BIBP3226 originally described as an NPY Yl selective receptor antagonist, showed an affinity for the human and rat NPFF1 receptor 10-60 times higher than for the corresponding NPFF2 receptors (Bonini et al., J. Biol. Chem 2000, 275 (50), 39324-31). From a series of compounds derived from the NPY Yl selective antagonist BIP3226, selective hNPFFl receptor antagonists were obtained which showed affinities of 40-80 nM (Mollereau et al., Europ. J. Pharmacol. 2002, 45, 245-56) ,
  • WO 02/24192 AI describes synthetic NPFF ligands of peptide structure, based on arginine as the central building block.
  • the products defined at the outset are potent and specific, low-molecular antagonists of neuropeptide FFl receptors with non-peptide or non-peptoid structures.
  • NSAIDs non-steroidal anti-inflammatory drugs
  • canabinoids canabinoids
  • opioids canabinoids
  • morphine derivatives bind to the ⁇ -opioid receptor and have an analgesic effect.
  • Opioid binding to the ⁇ -opioid receptor is accompanied by the release of neuropeptide FF.
  • the released NPFF weakens the analgesic effect of the administered opioids and leads to tolerance towards opioids.
  • increasingly higher opioid doses have to be administered as a result of this tolerance, which can ultimately lead to serious side effects.
  • NPFF1 receptor mainly located in the central nervous system and the NPFF2 receptor predominantly in the spinal cord.
  • Activation of the NPFF2 receptors shows an opioid-like analgesic effect. Blocking the NPPFl receptors by an antagonist prevents the development of tolerance to opioids and additionally increases their effect.
  • the products defined there are partly known and partly new, and are distinguished by the valuable pharmacological property of blocking the interaction of neuropeptide FF with the neuropeptide FF1 receptor subtype.
  • one of the carbon atoms in chain A is / are substituted in formula I, then can one of the carbon atoms has one or two (geminal) identical or different substituents; or several of the carbon atoms can each carry one or two (geminal) identical or different substituents.
  • a together with the thiazole ring can form a cyclopentathiazole, benzothiazole, cycloheptathiazole, pyranothiazole, thiazolopyridine, thiazoloazepine or thiazolooxane skeleton which contains only the two double bonds of the thiazole building block, such as a 4, 5, 6, 7-tetrahydrobenzothiazole-, 5,6,7,8-tetrahydro-4H-cycloheptathiazole-, 5, 6-dihydro-4H-cyclopentathiazole-, 6, 7-dihydro-4H-pyrano [4, 3-d] thiazole-, or 5, 6, 7, 8-tetrahydro-4H-thiazolo [4, 5-c] azepine backbone.
  • Alkanoyl alkenyl, alkoxy, alkoxyalkyl, alkoxyalkanoyl, alkoxyalkylcarbamoyl, alkoxyalkylthiocarbamoyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxycarbonylalkanoyl, alkylamido, alkylaminocarbonyl, alkylarylamino, alkylcarbamoyl, alkylthiocarbamoyl, alkylcarbonyl
  • Dialkylaminoalkylamido Dialkylaminoalkanoyl, diarylamino, formyl, formylalkyl, halogen, haloalkoxy, haloalkyl, Haloalkylamido, haloalkanoyl, halo-alkylamino, heteroarylamino, Heteroarylamido, Heterocyclylalkylamido, heteroarylaminocarbonyl, Heteroaryloxycarbonylalkyl, Heteroaryloxycarbonylalkylamido, hetero- aryloxycarbonylalkanoyl, heterocyclyl, heterocyclylamino, Heterocyclylamido, heterocyclylalkyl, heterocyclylalkanoyl, Heterocyclylamido, heterocyclylalkyl, heterocyclylalkanoyl, Heterocyclylalkylamino, heterocyclylalkylamido,
  • Heteroarylalkyl heteroarylalkanoyl, heteroarylalkylamino, heteroarylalkylamido, heteroyclylalkylaminocarbonyl, heterocyclylalkoxycarbonylalkyl, heterocyclylalkoxycarbonylalkanoyl, heterocyclylalkoxycarbonylalkylamino, heterocyclylalkoxy
  • R x are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, 1, 1-dimethylpropyl, or phenyl.
  • Hydrogen are different, then they preferably mean methyl or another lower alkyl radical.
  • Another subgroup of the compounds of the formula I can be represented by the general formula
  • R ' is alkyl, alkanoyl, alkenyl, alkynyl, alkoxycarbonylalkyl, Alkoxycarbonylaminoalkanoyl, alkylcarbamoyl, Alkoxycarbonylalkylcarbamoyl, Alkoxycarbonylalkylthiocarbamoyl, alkylthiocarbamoyl, mono- or disubstituted aminoalkanoyl, aryl, arylalkyl, arylalkoxycarbonyl, arylalkanoyl, arylcarbamoyl, alkoxyalkanoyl, alkylsulfonyl, arylthiocarbamoyl, aryloxycarbonylalkyl , Aryloxycarbonylalkanoyl, Aryloxycarbonylalkylcarbamoyl, Aryloxycarbonylalkylthio- carbamo
  • R ' is preferably methyl, ethyl, propyl, hexyl, 2, 2-dimethylpropionyl, cyclopropylmethyl, 2-
  • the present invention accordingly comprises these new substances as such and as therapeutic active substances; Processes for their manufacture;
  • one of the C atoms in chain A can carry one or two (ie geminal), identical or different, substituents; or several of the C atoms can each carry one or two (ie geminal), identical or different, substituents.
  • the substituent (s) can be selected from
  • substituent (s) can be selected from
  • Particularly preferred new fabrics are:
  • Also preferred new fabrics are:
  • alkyl denotes an unbranched or branched hydrocarbon radical of 1-8 C atoms.
  • Representative but not limiting examples of alkyl are methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl (or 2-
  • Methylpropyl n-pentyl (or n-amyl), isopentyl (or isoamyl, n-hexyl, n-heptyl, n-octyl and the like.
  • the alkyl radical can carry one or more substituents which are independently selected from alkenyl, alkoxy, Alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylenedioxy, alkylsulfinyl, alkylsulfinylalkyl, alkylsulfonyl, alkylsulfonylalkyl, alkylthio, alkylthioalkyl, alkynyl, amino, aminoalkyl, aminocarbonyl, aminocarbonylalkyl, aryl, arylalkoxyoxy, arylalkyloxyylylyloxy, Arylsulfinyl, arylsulfinylalkyl, arylsulfonyl,
  • lower alkyl denotes alkyl groups with 1-4 C atoms.
  • Representative but not limiting examples of lower alkyl are methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl and the like.
  • R a -R d denote substituents which are independently selected from hydrogen, alkyl, alkoxy, alkoxyalkyl, and the like.
  • Representative but not limiting examples of alkenyl are ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3- Butenyl, 4-pentenyl, 5-hexenyl and the like.
  • alkylenedioxy denotes an -O (CH 2 ) n O group, in which n denotes 1 or 2, the O atoms being connected to two adjacent C atoms of the molecular backbone.
  • alkylenedioxy are methylenedioxy, ethylenedioxy and the like.
  • alkynyl denotes an unbranched or branched hydrocarbon radical of 2-8 C atoms, in which at least one carbon-carbon triple bond (R a -C ⁇ CR b ) is present.
  • R a and R b denote substituents which are selected independently of one another from hydrogen,
  • alkynyl alkenyl, alkoxy, alkoxyalkyl, and the like.
  • alkynyl are acetylenyl, 1-propynyl, 2-propynyl, 1-butynyl, 3-butynyl, 2-pentynyl and the like.
  • alkoxy denotes an alkyl group that is linked via an oxygen bridge. Representative but not limiting examples of alkoxy are methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy.
  • alkoxyalkyl alone or in combination, denotes an alkoxy group which is linked via an alkyl radical. Representative but not limiting examples of alkoxyalkyl are tert-butoxymethyl, 2-ethoxyethyl, 2-methoxyethyl, and methoxymethyl.
  • alkoxycarbonyl denotes an alkoxy group which is linked via a carbonyl group.
  • Representative but not limiting examples of alkoxycarbonyl are methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl and the like.
  • alkoxycarbonylalkyl denotes an alkoxycarbonyl group which is linked via an alkyl radical.
  • alkoxycarbonylalkyl are methoxycarbonylpropyl, ethoxycarbonylbutyl, 2-tert-
  • alkylcarbonyl alone or in combination, denotes an alkyl group which is linked via a carbonyl group. Representative but not limitative
  • alkylcarbonyl examples include acetyl, 1-oxopropyl, 2,2-
  • alkylcarbonylalkyl alone or in
  • alkylcarbonyl group which is linked via an alkyl group.
  • alkylcarbonylalkyl 2-oxopropyl, 3, 3-dimethyl-2-oxopropyl, 3-oxobutyl, 3-
  • alkylcarbonyloxy denotes an alkylcarbonyl group which is linked via an oxygen bridge.
  • Representative but not limiting examples of alkylcarbonyloxy are acetyloxy, ethylcarbonyloxy, tert-butylcarbonyloxy and the like.
  • alkylsulfinyl alone or in combination, denotes an alkyl group which is linked via a sulfinyl group.
  • Representative but not limiting examples of alkylsulfinyl are methylsulfinyl, ethylsulfinyl and the like.
  • alkylsulfinylalkyl denotes an alkylsulfinyl group which is linked via an alkyl group.
  • Representative but not limiting examples of alkylsulfinylalkyl are methylsulfinylmethyl, ethylsulfinylmethyl and the like.
  • alkylsulfonyl denotes an alkyl group which is linked via a sulfonyl group.
  • Representative but not limiting examples of alkylsulfonyl are methylsulfonyl, ethylsulfonyl and the like.
  • alkylsulfonylalkyl denotes an alkylsulfonyl group which is linked via an alkyl group.
  • Representative but not limiting examples of alkylsulfonylalkyl are methylsulfonylmethyl, ethylsulfonylmethyl and the like.
  • alkylthio denotes an alkyl group which is linked via a thio group.
  • Representative but not limiting examples of alkylthio are methylsulfanyl, ethylsulfanyl, tert-butylsulfanyl, hexylsulfanyl and the like.
  • alkylthioalkyl denotes an alkylthio group linked through an alkyl group.
  • Representative but not limiting examples of alkylthioalkyl are methylsulfanyl-methyl, 2- (ethylsulfanyl) ethyl and the like.
  • amino denotes an -NR e R f group, where R e and R f are independently selected from hydrogen, alkyl, aryl, Arylalkyl, acyl, alkylcarbonyl, arylcarbonyl, carbamoyl, ureido, formyl, alkylsulfonyl, arylsulfonyl and the like.
  • aminoalkyl denotes an amino group which is linked via an alkyl group.
  • Representative but not limiting examples of aminoalkyl are aminomethyl, 2-aminoethyl, N-benzyl-N-methyl-aminomethyl, dimethylamino-methyl and the like.
  • aminocarbonyl denotes an amino group which is linked via a carbonyl group.
  • aminocarbonyl are dimethylaminocarbonyl, benzylaminocarbonyl, ethylaminocarbonyl and the like.
  • aminocarbonylalkyl alone or in
  • Combination refers to an aminocarbonyl group that is linked via an alkyl group.
  • aminocarbonylalkyl are 2-amino-2-oxoethyl, 2- (benzylamino) -2-oxoethyl, 2- (methylamino) -2-oxoethyl, 4-amino-4-oxobutyl, 4- (dimethylamino) -4-oxobutyl and the like
  • aryl denotes an aromatic carbocyclic group containing at least one aromatic ring, for example phenyl or biphenyl, or fused ring systems in which at least one ring is aromatic, for example 1,2,3,4 - tetrahydronaphthyl, naphthyl, anthryl, phenanthryl, fluorenyl and the like.
  • the aryl group can carry one or more substituents which are independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylenedioxy, alkylsulfinyl, alkylsulfinylalkyl, alkylsulfonyl,
  • arylalkenyl denotes an aryl group which is linked via an alkenyl group.
  • Representative but not limiting examples of arylalkenyl are 2-phenylethenyl, 3-phenylpropen-2-yl, 2-naphth-2-ylethenyl and the like.
  • arylalkoxy denotes an aryl group which is linked via an alkoxy group.
  • Representative but non-limiting examples of arylalkoxy are 2-phenylethoxy, 5-phenylpentyloxy, 3-naphth-2-ylpropoxy and the like.
  • arylalkyl denotes an aryl group which is linked via an alkyl group.
  • the aryl group can be unsubstituted or substituted.
  • Representative but not limiting examples of arylalkyl are benzyl, 2-phenylethyl, 3-phenylpropyl, 2-naphth-2-ylethyl and the like.
  • aryloxy denotes an aryl group that is linked via an oxygen bridge.
  • the aryl group can be unsubstituted or substituted.
  • Representative but not limiting examples of aryloxy are phenoxy, naphthyloxy, 3-bromophenoxy, 4-chlorophenoxy, 4-methylphenoxy, 3,4-dimethoxyphenoxy and the like.
  • the aryl group can be unsubstituted or substituted by definition.
  • carbamoyl alone or in combination, denotes a -C (0) NR e R f group.
  • thiocarbamoyl alone or in combination, denotes a -C (S) NR e R f group.
  • carbonyl alone or in combination, denotes a -C (0) group.
  • carboxyalkyl alone or in combination, denotes a carboxy group which is linked via an alkyl group.
  • Representative but not limiting examples of carboxyalkyl are carboxymethyl, 2-carboxyethyl, 3-carboxypropyl and the like.
  • cyano alone or in combination, denotes a -C ⁇ N group.
  • cyanoalkyl alone or in combination, denotes a cyano group which is linked via an alkyl group.
  • Representative but not limiting examples of cyanoalkyl are cyanomethyl, 2-cyanoethyl, 3-cyanopropyl and the like.
  • cycloalkyl alone or in combination, denotes a saturated cyclic
  • Hydrocarbon residue with 3-15 C atoms which can carry one or more substituents.
  • the substituents are selected independently of one another from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylenedioxy, alkylsulfinyl, alkylsulfinylalkyl, alkylsulfonyl, alkylsulfonylalkyl, alkylthio, alkylthioalkyl, alkynyl, amino, arylyl, arylyl, aminocyl, aminocyl, aminocyl, aminocyl, aminocyl, aminocyl, aminocarbonyl , Arylalkenyl, arylalkyloxy, arylalkyl, aryloxy, aryloxycarbonyl, ary
  • Cycloheptyl cyclooctyl.
  • one of the fused rings can be aromatic, such as 1-indanyl, 2-indanyl, tetrahydronaphthyl and the like.
  • cycloalkenyl and cycloalkynyl refer to cyclic hydrocarbon radicals which contain at least one carbon-carbon double or triple bond. Like the cycloalkyl radicals, these radicals can carry one or more substituents.
  • formylalkyl denotes a formyl group which is linked via an alkyl group.
  • Representative but not limiting examples of formylalkyl are formylmethyl, 2-formylethyl, and the like.
  • halo or halogen, alone or in combination, denotes fluorine, bromine, chlorine and iodine.
  • haloalkyl alone or in combination, denotes an alkyl group in which at least one
  • Hydrogen atom is replaced by halogen.
  • Representative but not limiting examples of haloalkyl are chloromethyl, 2-fluoroethyl, trifluoromethyl, pentafluoroethyl, 2-chloro-3-fluoropentyl and the like.
  • haloalkoxy denotes an alkoxy group in which at least one Hydrogen atom is replaced by halogen.
  • Representative but not limiting examples of haloalkoxy are chloromethoxy, 2-fluoroethoxy, trifluoromethoxy, pentafluoroethoxy and the like.
  • heterocyclyl denotes a monocyclic, bicyclic or polycyclic ring system with up to 15 ring atoms, containing at least one heteroatom independently selected from nitrogen, oxygen, or sulfur, the ring (s) saturated, partially can be unsaturated or unsaturated or aromatic.
  • heterocyclyl are furyl, imidazolyl, imidazolinyl, imidazolidinyl, isothiazolyl, isoxazolyl, morpholinyl, oxadiazolyl, oxazolyl, oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrrolyl, pyrrolinyl , Pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, thiadiazolyl, thiazolyl, thiazolinyl, thiazolidinyl, thienyl, thiomorpholinyl, 1,1-
  • Dioxothiomorpholinyl benzimidazolyl, benzothiazolyl, benzothienyl, benzoxazolyl, benzofuranyl, indolyl, indolinyl, isobenzofuranyl, isobenzothienyl, isoindolyl, isoindolinyl, isoquinolinyl, quinolinyl and the like.
  • the heterocylyl radicals may be selected from one another, where alkenyloxy may be one or more, wherein Alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylenedioxy, alkylsulfinyl, alkylsulfinylalkyl, alkylsulfonyl,
  • heteroaryl alone or in combination, is a special case of heterocyclyl and denotes a monocyclic, bicyclic or polycyclic ring system, in which the or at least one ring is heteroaromatic.
  • heterocyclylalkenyl denotes a heterocyclyl group which is linked via an alkenyl group.
  • Representative but not limiting examples of heterocyclylalkenyl are 2-pyrid-3-ylethenyl, 3-quinolin-3-ylpropen-2-yl, 5-pyrid-4-ylpentylen-4-yl and the like.
  • heterocyclylalkoxy alone or in
  • Combination denotes a heterocyclyl group which is linked via an alkoxy group.
  • Representative but not limiting examples of heterocyclylalkoxy are 2-pyrid-3-ylethoxy, 3-quinolin-3-ylpropoxy, 5-pyrid-4-ylpentyloxy and the like.
  • heterocyclylalkyl denotes a heterocyclyl group which is linked via an alkyl group by definition.
  • heterocyclylalkyl 2-pyrid-3-ylmethyl, 2-pyrimidin-2-ylpropyl and the like.
  • heterocyclyloxy denotes a heterocyclyl group which is linked via an oxygen bridge.
  • Representative but not limiting examples of heterocyclyloxy are pyrid-3-yloxy, quinolin-3-yloxy and the like.
  • hydroxy or "hydroxyl”, alone or in combination, denote an -OH group.
  • hydroxyalkyl alone or in combination, denotes an alkyl group in which at least one hydrogen atom is replaced by a hydroxyl group.
  • Representative but not limiting examples of hydroxyalkyl are hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-ethyl-4-hydroxyheptyl and the like.
  • nitro alone or in combination, denotes a -N0 2 group.
  • oxy alone or in combination, denotes a -0- group.
  • Acid addition salts as pharmaceutically usable salts of acidic compounds of formula I with bases, as pharmaceutically usable esters of hydroxyl or carboxy group-containing compounds of formula I and as hydrates or solvates thereof.
  • bases as pharmaceutically usable esters of hydroxyl or carboxy group-containing compounds of formula I and as hydrates or solvates thereof.
  • the acid addition salts are made from the free bases by means of inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like. preferably hydrochloric acid or hydrobromic acid, or by means of organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, tartaric acid, salicylic acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, p-toluenesulfonic acid and the like.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like.
  • organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, tartaric acid, salicylic acid, cit
  • Preferred salts with inorganic bases are, but not exclusively, sodium, potassium, lithium, ammonium, calcium, magnesium salts and the like.
  • Preferred salts with organic bases are, but not exclusively, salts with primary, secondary and tertiary, if appropriate substituted amines, including all naturally occurring substituted amines, with cyclic amines and with basic ion exchange resins such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polyamine resins and the like compounds of the formula I, which contain an acidic group, can also be present as zwitterions.
  • esters of compounds of the formula I containing hydroxyl or carboxy groups are also mentioned at the outset.
  • “Pharmaceutically usable esters” means that corresponding functional groups in compounds of the formula I are derivatized to ester groups in such a way that they are transformed back into their active form in vivo. On the one hand, COOH groups can be esterified.
  • suitable such esters are the alkyl and aralkyl esters. Preferred such esters are the methyl, ethyl, propyl, butyl and benzyl esters and the (R / S) -1- [(isopropoxycarbonyl) oxy] ethyl esters.
  • ethyl esters and the isomeric butyl esters are particularly preferred.
  • OH groups can be esterified.
  • examples of such compounds contain physiologically acceptable and metabolically labile ester groups, such as Methoxymethyl ester, methyl thiomethyl ester, pivaloyloxymethyl ester and similar ester groups.
  • Hamster cells (Chinese Hamster Ovary cells, CHOSP10) suitable for neuropeptide FF receptor binding studies, which each produce the NPFF1 or NPFF2 receptor, were grown under standard cell culture conditions.
  • the binding test was carried out in a final volume of 250 ⁇ l. 100 ⁇ l membrane buffer mix corresponding to 35 ⁇ g
  • Protein contents were mixed with 95 ⁇ l binding buffer (50 mM Tris pH 7.4, 60 mM NaCl, 0.1% protease free BSA, 0.01% NaN 3 ). After adding 5 ⁇ l of a concentration of test substance per measurement point, 0.2 nM 125 I-Tyrl-NPFF (NEN, NEX381) was added per measurement point in 50 ⁇ l. After incubating for 90 minutes at room temperature, the samples were aspirated through a GF / C filter (Millipore (MAHFC1H60)) and the filter was washed with ice-cold binding buffer with 3 times 300 ⁇ l (Packard Filtermate). After adding 55 ⁇ l
  • Microscint 40 (Packard 6013641) scintillation fluid the measuring points were quantified in the gamma counter (Packard, Top Count NXT).
  • Non-specific binding was determined in the presence of 1 ⁇ M unlabeled neuropeptide FF. Specific binding is defined as the difference between total and non-specific binding. IC 50 values are defined as the concentration of the antagonist which displaces 50% of the 12S I-labeled neuropeptide FF. This concentration is determined by linear regression analysis after logit / log transformation of the binding values.
  • Preferred compounds according to the invention show IC 50 values below 1000 nM in the receptor binding study described above, particularly preferred compounds show IC 50
  • the substances defined there are valuable for the treatment of pain, hypersensitivity to pain (hyperalgesia) and chronic, acute, long-lasting or temporary pain, due to their ability to block the neuropeptide FF receptors, these pains being operative, traumatic, or can be of pathological origin. Above all, they complement the common treatment methods for chronic pain with the advantage of preventing undesired opioid tolerance and / or opioid dependence.
  • the compounds can also be used to regulate insulin release, food intake, memory functions, blood pressure and the electrolyte and energy balance and to treat urinary incontinence.
  • the substances defined at the outset can be brought into suitable pharmaceutical dosage forms by methods which are generally known and familiar to any person skilled in the art.
  • dosage forms are, for example, tablets, coated tablets, dragees, capsules, injection solutions, etc.
  • Excipients and auxiliaries suitable for producing such pharmaceutical dosage forms are also generally known and familiar to any person skilled in the art.
  • these dosage forms can also contain further pharmacologically active compounds.
  • the dosage of the substances defined at the outset or of the dosage forms containing them must be adjusted by the attending physician to the respective needs of the patient.
  • a daily dose of 0.1-20 mg, preferably 0.5-5 mg of one of the substances defined at the beginning per kg of body weight of the patient should be appropriate.
  • the guanidine derivatives of the general formula I and the corresponding starting materials and intermediates can be prepared using methods known in organic synthesis and can be isolated and purified using known techniques such as precipitation, chromatography, crystallization, preparative reversed-phase HPLC, etc.
  • Any stereoisomer mixtures obtained, such as racemates, can be separated by generally customary methods, preferably by chromatography on a chiral phase.
  • 2-Imino-4-thiobiuret of the formula 3 is subjected to cyclocondensation, optionally splitting off the protective group attached to the nitrogen atom which may be present from the compound obtained, optionally substituting this nitrogen atom appropriately with an agent which gives off a radical R 'and optionally a basic compound obtained in a pharmaceutically usable acid addition salt, or a compound containing an acid group obtained in a pharmaceutically usable salt with a base, or a compound containing a hydroxyl or carboxy group obtained in one transferred pharmaceutically usable ester and optionally the product obtained is converted into a hydrate or solvate.
  • Guanidine derivatives of the formula I and the corresponding intermediates are carried out in solution using an organic solvent.
  • Protective groups are introduced and removed using typical methods known to those skilled in the art (T.W. Greene & P.G.M. Wuts in
  • cycloalkanones (1) can be halogenated to the carbonyl group in position ⁇ using known methods.
  • the subsequent cyclocondensation of ⁇ -halo-oxo compounds (2) with a thiourea derivative, such as. B. 2-imino-4-thiobiuret (3) takes place in a known manner and leads to the desired guanidine derivatives of the formula I (J. Med. Chem. 1991, 34 (3), 914-918; J. Med. Chem. 1994, 37 (8), 1189-1199).
  • heterocyclic oxo compounds (1) can be used in an analogous manner to the corresponding ones
  • Target compounds of Formula I are implemented. It should be noted here that an -NH group present in A of the starting product (cf. formula 4 below) should be provided with a common protective group (PG), see scheme 2 below:
  • PG common protective group
  • cyclic azaketones of the formula 4 required are known in some cases from the literature (Yokoo et al., Bull. Chem. Soc. Japan 1959, 29, 631; Griss et al., DE 2206385, published February 10, 1972) or can be analogous to the precursor for example N-07 can be manufactured.
  • the R 'radicals defined at the outset are known under known conditions by means of the corresponding R' releasing reagents, such as, for example, alkyl halides, carboxylic acid halides or anhydrides, or also carboxylic acids in the presence of coupling reagents and with base as Auxiliary reagent, chloroformates, sulfonyl halides, Isocyanates, isothiocyanates and the like. Reacted to the corresponding compound of formula III.
  • the corresponding R' releasing reagents such as, for example, alkyl halides, carboxylic acid halides or anhydrides, or also carboxylic acids in the presence of coupling reagents and with base as Auxiliary reagent, chloroformates, sulfonyl halides, Isocyanates, isothiocyanates and the like.
  • Suitable organic solvents are those which are inert under the chosen reaction conditions. These are preferably ethers, such as diethyl ether, dioxane, tetrahydrofuran or glycol dimethyl ether; or alcohols, such as, for example, methanol, ethanol, propanol, isopropanol, butanol, isobutanol or tert-butanol; or hydrocarbons, such as benzene, toluene, xylene, hexane,
  • Cyclohexane or petroleum fractions or halogenated hydrocarbons, such as dichloromethane, trichloromethane, carbon tetrachloride, dichlorethylene, trichlorethylene or chlorobenzene; or also ethyl acetate, triethylamine, pyridine, dimethyl sulfoxide, dimethyl formamide, hexamethyl phosphoramide, acetonitrile, acetone or nitromethane. Mixtures of the solvents mentioned can also be used.
  • Bases that can be used for the processes described are generally inorganic or organic bases.
  • Alkali metal hydroxides for example sodium or potassium hydroxide
  • alkaline earth metal hydroxides for example barium hydroxide
  • alkali metal carbonates such as sodium carbonate or potassium carbonate
  • alkaline earth metal carbonates such as calcium carbonate, or alkali metal or
  • Alkaline earth metal alkoxides such as sodium or potassium methoxide, sodium or potassium ethoxide or potassium ert-butoxide, or organic amines, for example trialkyl -amines, such as triethylamine, or heterocyclic amines, such as 1,4-diazabicyclo [2.2.2] octane (DABCO), 1,8-diazabicyclo [5.4.0] undec-7-ene (DBU), pyridine, 4-dimethylaminopyridine , N-methyl-piperidine or N-methylmorpholine. It is also possible to use alkali metals, such as sodium, or their hydrides, such as sodium hydride.
  • the bases mentioned can, where appropriate, be used as an acid-binding auxiliary.
  • Dehydrating reagents can serve as coupling reagents, for example carbodiimides such as
  • bases such as triethylamine or N-ethyl
  • Example C-01 Analogously to the preparation of Example C-01, the compounds according to Examples C-02 to C-73 in Table 3 are prepared starting from the corresponding ⁇ -bromo or ⁇ -chloro ketones.
  • N-butyllithium is added dropwise to a solution of diisopropylamine (5.5 mmol) in dry tetrahydrofuran which is cooled to 0 ° C. After the addition is complete
  • the title compound is implemented as a crude product without further characterization.
  • the title compound is implemented as a crude product without further characterization.
  • the title compound is implemented as a crude product without further characterization.
  • the title link is implemented as a raw product without further characterization.
  • the title compound is implemented as a crude product without further characterization.
  • 2-ethyl-2-methyl-cyclohexanone precursor for example C-27
  • the alkylation of 2-methylcyclohexanone with ethyl iodide is carried out in an analogous manner to that described above for the preparation of 2, 2-dimethyl-cyclohexanone.
  • Prep LC equipped with a Waters 600 controller, Waters 2767 sample manager, Waters 996 mass spectrometer and photodiode array detector).
  • Example C-31 the compounds of Examples C-32 to C-41 listed in Table 3 are obtained by reacting 2-guanidino-4, 5, 6, 7-tetrahydro-benzothiazole-4-carboxylic acid with the corresponding amines in the presence a coupling reagent such as O- (benzotriazol-1-yl) - N, N, N ', N' -tetramethyluronium hexafluorophosphate.
  • a coupling reagent such as O- (benzotriazol-1-yl) - N, N, N ', N' -tetramethyluronium hexafluorophosphate.
  • Example C-31 Analogously to Example C-31, the compounds of Examples C-43 to C-46 listed in Table 3 are reacted with 2-guanidino-4, 5, 6, 7-tetrahydro-benzothiazole-4-carboxylic acid with the corresponding amines in the presence a coupling reagent such as O- (benzotriazol-1-yl) - N, N, N ', N' -tetramethyluronium hexafluorophosphate.
  • a coupling reagent such as O- (benzotriazol-1-yl) - N, N, N ', N' -tetramethyluronium hexafluorophosphate.
  • the title compound is based on 4-phenyl-spiro [5.5] undecan-1-one instead of spiro [5.5] undecan-1-one in an analogous manner to N- (tetrahydro-benzothiazol-2-yl-4-spiro-cyclohexane ) -guanidine.
  • 4,4-diphenylcyclohexanone (precursor for example C-49) 4,4-diphenylcyclohexanone is prepared in an analogous manner to that described for the preparation of 4,4-dimethylcyclohexanone: t R 3.68 min (LC-1); IT I-
  • 1,4-dioxa-spiro [4.5] dec-7-en-8-yl-trifluoromethanesulfonic acid ester To a solution of lithium bis (trimethylsilyl) amide (IM in tetrahydrofuran, 1.1 mmol) in dry tetrahydrofuran, cooled to -78 ° C., 1,4-dioxa-spiro [4.5] decan-8-one (1 mmol) , dissolved in tetrahydrofuran (2 ml). The mixture is stirred for a further 1.5 hours at -78 ° C.
  • 8- (4-Fluoro-phenyl) -1, -dioxa-spiro [4.5] dec-7-ene is hydrogenated on Pd / C with hydrogen. After filtering off the catalyst through Celite and evaporating the solvent, 8- (4-fluorophenyl) -1, 4-dioxa-spiro [4.5] decane is obtained in quantitative yield: t R 3.65 min (LC-1); IT I-
  • Examples C-55 to C-66 are prepared in an analogous manner to that described above for the preparation of 4- (4-fluorophenyl) cyclohexanone.
  • Trimethyl- (4-phenyl-cyclohex-1-enyloxy) -silane (7.27 mmol) and tert-butyl chloride (7.85 mmol) are placed in dichloromethane under nitrogen and cooled to -45 ° C.
  • the reaction mixture is diluted with dichloromethane and washed with ice water. The organic phase is dried over sodium sulfate and the solvent is removed in vacuo.
  • Example N-02 Analogously to Example N-02, the compounds of Examples N-03 to N-10 listed in Table 4 are obtained by reaction of N- (4, 5, 6, 7-tetrahydro-thiazolo [5, 4-c] pyridine-2- yl) -guanidine with the corresponding alkyl halides ("R 1 reagents").
  • N-Benzyl-azepan-3-one precursor for example N-07
  • N-benzylglycine ethyl ester (1.87 ml) and 5-bromovaleric acid ethyl ester (1.92 ml) are in Dimethylformamide (100 ml) dissolved and stirred in the presence of potassium carbonate (1.66 g) for 2 days at room temperature.
  • the reaction is quenched with saturated aqueous ammonium chloride solution and extracted with ethyl acetate. After drying over Sodium sulfate, the combined organic phases are evaporated.
  • Example N-II Analogously to Example N-II, the compounds of Examples N-13 to N-33 listed in Table 4 are obtained by reaction of N- (4, 5, 6, 7-tetrahydro-thiazolo [5, 4-c] pyridine-2 - yl) -guanidine with the corresponding acid chlorides ("R'-reagents").
  • Example N-12 Analogously to Example N-12, the compounds of Examples N-19 to N-21 listed in Table 4 are obtained by reaction of N- (4, 5, 6, 7-tetrahydro-thiazolo [5, -c] pyridin-2 -yl ) -guanidine with the corresponding carboxylic acids ("R'-reagents”) in the presence of benzotriazolyloxy-tris (dimethylamino) phosphonium hexafluorophosphate as coupling reagent.
  • R'-reagents carboxylic acids
  • Example N-22 Analogously to Example N-22, the compound of Example N-23 listed in Table 4 is obtained by reaction of N- (4, 5, 6, 7-tetrahydro-thiazolo [5, 4-c] pyridin-2-yl) guanidine made with butyl chloroformate ("R 'reagent").
  • Example N-24 Analogously to Example N-24, the compounds of Examples N-25 and N-26 listed in Table 4 are obtained by reaction of N- (4, 5, 6, 7-tetrahydro-thiazolo [5, 4-c] pyridine-2 - yl) -guanidine with the corresponding sulfonyl chlorides ("R 1 reagents").
  • Example N-27
  • Dimethylformamide (0.5 ml) is added diisopropylethylamine (0.2 mmol) and after 5 min phenyl isocyanate (0.11 mmol).
  • the reaction mixture is at for 3 hours
  • Example N-27 the compounds of Examples N-28 and N-29 listed in Table 4 are obtained by reaction of N- (4, 5, 6, 7-tetrahydro-thiazolo [5, 4-c] pyridine-2- yl) -guanidine dihydrochloride with the "R 1 reagents" tert-butyl isocyanate or pentyl isocyanate.
  • Benzylamine (0.1 mmol), dissolved in dimethylformamide (0.3 ml), is added under argon to a solution of 1'-thiocarbonyldiimidazole (0.1 mmol) in dimethylformamide (0.5 ml).
  • a solution of N- (4, 5, 6, 7-tetrahydrothiazolo [5, 4-c] pyridin-2-yl) guanidine dihydrochloride 0.1 mmol
  • diisopropylethylamine (0.2 mmol ) added to the reaction mixture in dimethylformamide. This is stirred for a further 16 hours at room temperature and then quenched with saturated aqueous sodium carbonate solution.
  • Example N-30 Analogously to Example N-30, the compounds of Examples N-31 to N-33 listed in Table 4 are passed through
  • Preparative separations of substance mixtures are carried out on a preparative LC-MS system (Waters Prep LC-MS equipped with a Waters 600 controller, Waters 2767 sample manager, Waters 996 mass spectrometer and photodiode array detector).
  • An Xterra Prep MS C18 column (5 ⁇ m particle size, length 50 mm, diameter 19 mm) with a linear gradient of water / 0.06% formic acid (A) and acetonitrile / 0.06% formic acid (B) and a flow rate of 20 is used ml / min.
  • the ⁇ NMR spectra are on a Varian Oxford 300
  • Shift ⁇ is shifted in ppm downfield from the signal from tetramethylsilane as a reference, the residual signals from deuterated serve as internal standard
  • the compounds produced are analyzed by means of reversed-phase HPLC on a Waters Alliance
  • LC-1 GROM-SIL 120 ODS-4 HE HPLC column (particle size 3 ⁇ m, column length 30mm, diameter 2mm), with a linear gradient with water / 0.06% formic acid (A) and acetonitrile / 0.06% formic acid (B) from 5% to 95% B in 3 min. with a flow rate of 0.75 ml / min.
  • LC-2 XTerra MS C18 HPLC column (particle size 5 ⁇ m, column length 50 mm, diameter 2.1 mm), with a linear gradient with water / 0.06% formic acid (A) and
  • Acetonitrile / 0.06% formic acid (B) from 5% to 95% B in 2.5 min. with a flow rate of 0.75 ml / min.
  • Example structure name 9 ** . "Molecular (HPLC r Product weight Meth.) [M + H] [MH] -
  • N-02 TCO " - NH tetrahydro-thiazolo [5.4-1 bromohexane 282.18 / 280.33 281.4 (LC-1) vc] pyridin-2-yl) guanidine
  • N-31 isopropy amine _ no . .. _ .. 298.86 / 296.29 vv * 298.4 (LC-1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/CH2004/000175 2003-03-20 2004-03-22 Guanidinderivate und ihre verwendung als neuropeptid ff rezeptor-antagonisten WO2004083218A1 (de)

Priority Applications (8)

Application Number Priority Date Filing Date Title
MXPA05009855A MXPA05009855A (es) 2003-03-20 2004-03-22 Derivados de guanidina y sus usos como antagonistas del receptor de neuropeptido ff.
AU2004222224A AU2004222224A1 (en) 2003-03-20 2004-03-22 Guanidine derivatives and use thereof as neuropeptide FF receptor antagonists
BRPI0408357-1A BRPI0408357A (pt) 2003-03-20 2004-03-22 uso de derivados de guanidina, compostos, produto medicinal, uso de compostos, e, método para a preparação de compostos
JP2006504158A JP2006520330A (ja) 2003-03-20 2004-03-22 グアニジン誘導体および神経ペプチドｆｆ受容体拮抗物質としてのそれらの使用
EP04722212A EP1608662A1 (de) 2003-03-20 2004-03-22 Guanidinderivate und ihre verwendung als neuropeptid ff rezeptor-antagonisten
CA002518679A CA2518679A1 (en) 2003-03-20 2004-03-22 Guanidine derivatives and use thereof as neuropeptide ff receptor antagonists
US10/549,685 US7727979B2 (en) 2003-03-20 2004-03-22 Guanidine derivatives and their use as neuropeptide FF receptor antagonists
NO20054743A NO20054743L (no) 2003-03-20 2005-10-14 Guanidinderivater og anvendelse derav som neuropeptid FF reseptor antagonister

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH466/03 2003-03-20
CH4662003 2003-03-20

Publications (1)

Publication Number Publication Date
WO2004083218A1 true WO2004083218A1 (de) 2004-09-30

Family

ID=32996985

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CH2004/000175 WO2004083218A1 (de) 2003-03-20 2004-03-22 Guanidinderivate und ihre verwendung als neuropeptid ff rezeptor-antagonisten

Country Status (15)

Country Link
US (1) US7727979B2 (ja)
EP (1) EP1608662A1 (ja)
JP (1) JP2006520330A (ja)
KR (1) KR20050107611A (ja)
CN (1) CN100355758C (ja)
AR (1) AR043662A1 (ja)
AU (1) AU2004222224A1 (ja)
BR (1) BRPI0408357A (ja)
CA (1) CA2518679A1 (ja)
CL (1) CL2004000553A1 (ja)
MX (1) MXPA05009855A (ja)
NO (1) NO20054743L (ja)
RU (1) RU2337911C2 (ja)
TW (1) TW200510434A (ja)
WO (1) WO2004083218A1 (ja)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005092871A2 (en) * 2004-03-19 2005-10-06 Dipharma S.P.A. Intermediates for the preparation of pramipexole
WO2008008517A2 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. Bridged diazepan orexin receptor antagonists
WO2008069997A1 (en) 2006-12-01 2008-06-12 Merck & Co., Inc. Substituted diazepan compounds as orexin receptor antagonists
WO2008143856A1 (en) 2007-05-18 2008-11-27 Merck & Co., Inc. Oxo bridged diazepan orexin receptor antagonists
WO2008147518A1 (en) 2007-05-23 2008-12-04 Merck & Co., Inc. Pyridyl piperidine orexin receptor antagonists
WO2008150364A1 (en) 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US7727979B2 (en) 2003-03-20 2010-06-01 Actelion Pharmaceuticals Ltd. Guanidine derivatives and their use as neuropeptide FF receptor antagonists
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2012116145A1 (en) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051725A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9156819B2 (en) 2011-10-19 2015-10-13 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-nitrile orexin receptor antagonists
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
US10344002B2 (en) 2016-09-26 2019-07-09 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
WO2021023813A1 (en) 2019-08-06 2021-02-11 Domain Therapeutics 5-heteroaryl-pyridin-2-amine confounds as neuropeptide ff receptor antagonists

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7153653B2 (ja) * 2017-02-14 2022-10-14 リサーチ トライアングル インスティテュート プロリン系神経ペプチドｆｆ受容体モジュレーター
AU2019232247A1 (en) * 2018-03-09 2020-10-01 Centre National De La Recherche Scientifique Hybrid mu opioid receptor and neuropeptide FF receptor binding molecules, their methods of preparation and applications in therapeutic treatment
CN110093348B (zh) * 2018-12-05 2022-11-29 西北工业大学 增强小鼠NPFFR2基因表达的shRNA
CN112341404B (zh) * 2019-08-09 2023-05-23 成都苑东生物制药股份有限公司 噻唑类衍生物或盐、异构体、其制备方法及用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1140387A (en) * 1965-07-23 1969-01-15 Thomae Gmbh Dr K 4,5,6,7-tetrahydro-thiazolo-[5,4-c]pyridines
US4624956A (en) * 1983-12-16 1986-11-25 Farmitalia Carlo Erba Ulcer and gastric secretion inhibiting 4,5,6,7-tetrahydrothiazole[5,4-c]pyridine derivatives
US4716228A (en) * 1985-03-23 1987-12-29 Farmitalia Carlo Erba S.P.A. Condensed 2-substituted thiazole derivatives
EP0321191A2 (en) * 1987-12-18 1989-06-21 Pfizer Inc. Heterocyclic-substituted quinoline-carboxylic acids
WO2002024192A1 (fr) * 2000-09-25 2002-03-28 Institut National De La Sante Et De La Recherche Medicale Ligands dipeptidiques du recepteur npff pour le traitement de la douleur et des hyperalgies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795257A (fr) 1972-02-10 1973-08-09 Thomae Gmbh Dr K Nouveaux oxazols
JPS60226810A (ja) 1984-04-25 1985-11-12 Ikeda Mohandou:Kk 抗潰瘍剤
JPS6233158A (ja) 1985-08-02 1987-02-13 Shionogi & Co Ltd ベンズイミダゾ−ル誘導体および抗潰瘍剤
KR0168978B1 (ko) * 1995-07-12 1999-01-15 김종인 헤테로고리 접합 티아졸 유도체
JPH0959258A (ja) * 1995-08-11 1997-03-04 Ono Pharmaceut Co Ltd グアニジル誘導体
CL2004000553A1 (es) 2003-03-20 2005-02-04 Actelion Pharmaceuticals Ltd Uso de compuestos derivados de guanidina como antagonistas del receptor de neuropeptido ff; compuestos derivados de guanidina; procedimientos de preparacion; y composicion farmaceutica que los comprende.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1140387A (en) * 1965-07-23 1969-01-15 Thomae Gmbh Dr K 4,5,6,7-tetrahydro-thiazolo-[5,4-c]pyridines
US4624956A (en) * 1983-12-16 1986-11-25 Farmitalia Carlo Erba Ulcer and gastric secretion inhibiting 4,5,6,7-tetrahydrothiazole[5,4-c]pyridine derivatives
US4716228A (en) * 1985-03-23 1987-12-29 Farmitalia Carlo Erba S.P.A. Condensed 2-substituted thiazole derivatives
EP0321191A2 (en) * 1987-12-18 1989-06-21 Pfizer Inc. Heterocyclic-substituted quinoline-carboxylic acids
WO2002024192A1 (fr) * 2000-09-25 2002-03-28 Institut National De La Sante Et De La Recherche Medicale Ligands dipeptidiques du recepteur npff pour le traitement de la douleur et des hyperalgies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARINKO P ET AL: "A convenient synthesis of 4-aminomethyl-4,5,6,7-tetrahydro- 1,3-benzothiazole arginine side-chain mimetics", TETRAHEDRON LETTERS, vol. 42, no. 50, 10 December 2001 (2001-12-10), pages 8911 - 8913, XP004322573 *
SCARPONI U ET AL: "Bicyclic compounds with potential antiulcer and/or antisecretory activity. III - 2-Substituted tetrahydrothiazolo- [5,4-c]pyridines", IL FARMACO, vol. 43, no. 7-8, 1988, pages 575 - 596, XP002249434 *

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7727979B2 (en) 2003-03-20 2010-06-01 Actelion Pharmaceuticals Ltd. Guanidine derivatives and their use as neuropeptide FF receptor antagonists
WO2005092871A2 (en) * 2004-03-19 2005-10-06 Dipharma S.P.A. Intermediates for the preparation of pramipexole
WO2005092871A3 (en) * 2004-03-19 2005-12-01 Dipharma Spa Intermediates for the preparation of pramipexole
US8203002B2 (en) 2004-03-19 2012-06-19 Dipharma S.P.A. Intermediates for the preparation of pramipexole
EP2289885A1 (en) * 2004-03-19 2011-03-02 Dipharma Francis S.r.l. Intermediates for the preparation of pramipexole
US7741490B2 (en) 2004-03-19 2010-06-22 Dipharma S.P.A. Intermediates for the preparation of pramipexole
WO2008008517A2 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. Bridged diazepan orexin receptor antagonists
WO2008069997A1 (en) 2006-12-01 2008-06-12 Merck & Co., Inc. Substituted diazepan compounds as orexin receptor antagonists
EP2392572A1 (en) 2006-12-01 2011-12-07 Merck Sharp & Dohme Corp. Substituted diazepan compounds as orexin receptor antagonists
WO2008143856A1 (en) 2007-05-18 2008-11-27 Merck & Co., Inc. Oxo bridged diazepan orexin receptor antagonists
US8569311B2 (en) 2007-05-23 2013-10-29 Merch Sharp & Dohme Corp. Pyridyl piperidine orexin receptor antagonists
WO2008150364A1 (en) 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
WO2008147518A1 (en) 2007-05-23 2008-12-04 Merck & Co., Inc. Pyridyl piperidine orexin receptor antagonists
US8242121B2 (en) 2007-05-23 2012-08-14 Merck Sharp & Dohme Corp. Pyridyl piperidine orexin receptor antagonists
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP3243385A1 (en) 2011-02-25 2017-11-15 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012116145A1 (en) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US9156819B2 (en) 2011-10-19 2015-10-13 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-nitrile orexin receptor antagonists
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051725A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US10344002B2 (en) 2016-09-26 2019-07-09 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
WO2021023813A1 (en) 2019-08-06 2021-02-11 Domain Therapeutics 5-heteroaryl-pyridin-2-amine confounds as neuropeptide ff receptor antagonists

Also Published As

Publication number Publication date
US7727979B2 (en) 2010-06-01
BRPI0408357A (pt) 2006-03-21
US20060194788A1 (en) 2006-08-31
EP1608662A1 (de) 2005-12-28
JP2006520330A (ja) 2006-09-07
RU2337911C2 (ru) 2008-11-10
KR20050107611A (ko) 2005-11-14
TW200510434A (en) 2005-03-16
CN1761673A (zh) 2006-04-19
CL2004000553A1 (es) 2005-02-04
RU2005132308A (ru) 2006-03-20
CA2518679A1 (en) 2004-09-30
MXPA05009855A (es) 2005-12-06
CN100355758C (zh) 2007-12-19
NO20054743L (no) 2005-10-14
AR043662A1 (es) 2005-08-03
AU2004222224A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
WO2004083218A1 (de) Guanidinderivate und ihre verwendung als neuropeptid ff rezeptor-antagonisten
DE69833224T2 (de) Benzothiazole als protein tyrosin-kinase inhibitoren
JP6630374B2 (ja) τリン酸化を阻害する方法
ES2338697T3 (es) Compuestos organicos para el tratamiento de condiciones inflamatorias o alergicas.
TW201815766A (zh) 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
CN112312904A (zh) 螺环化合物
JP2017002085A (ja) スピロ−オキシインドール化合物のエナンチオマーおよび治療剤としてのその使用
JP2008502693A (ja) 三環式化合物およびｍｇｌｕｒ１アンタゴニストとしてのそれらの使用
EP1831197A2 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
JP2017523193A (ja) 核内受容体に対して活性な化合物
EP2322527A1 (de) Triazolderivate
DE60022895T2 (de) Pdgf-rezeptor-kinase hemmende verbindungen, deren herstellung, reinigung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
US10105373B2 (en) Fused triterpene compounds and uses thereof
JP6427192B2 (ja) 位相変位睡眠障害を処置するためのＶ１ａアンタゴニスト
KR20100051678A (ko) 글루타메이트성 시냅스 반응을 향상시키기 위한 비시클릭 아미드
TW202115083A (zh) 肽醯精胺酸脫亞胺酶抑制劑及其用途
JP2024096843A (ja) イオンチャネル阻害化合物を使用して過敏性咳またはかゆみを治療する方法
DE69925270T2 (de) Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten
JP5969003B2 (ja) ２−オキソ−１−イミダゾリジニルイミダゾチアジアゾール誘導体
EP1204414A2 (de) Verwendung von morphinderivaten als arzneimittel zur behandlung von neuropatishchen probleme
DE69514315T2 (de) AZABICYCLOALKYLDERIVATE VON IMIDAZO[1,5-a]INDOL-3-ONE ALS 5HT3 ANTAGONISTEN
EP1663993A1 (de) Guanidinderivate
WO2023166349A2 (zh) 苯基脲类衍生物及其医药用途
ZA200508486B (en) Guanidine derivatives and use thereof as neuropeptide FF receptor antagonists
WO2022164822A1 (en) Compounds for disease treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004722212

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020057016769

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006504158

Country of ref document: JP

Ref document number: 2518679

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1-2005-501659

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 170862

Country of ref document: IL

Ref document number: PA/a/2005/009855

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 20048074476

Country of ref document: CN

Ref document number: 2006194788

Country of ref document: US

Ref document number: 10549685

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 542942

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004222224

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2682/CHENP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200508486

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2005132308

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2004222224

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020057016769

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004722212

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0408357

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10549685

Country of ref document: US